- Joined
- Jul 10, 2014
- Messages
- 17,036
- Reaction score
- 27,399
So we see that in a valid study, MK677 at 25mgs does spike glucose levels and prolactin. The glucose ranges were 5-10% elevations only and the prolactin increases were higher at 27% average. The effects seemed to affect both women and men equally.
From the laboratory perspective, hyperglycemia was the most common adverse effect after MK-677 treatment. In the 9-week study, five patients (6%) had their dose reduced from 25 mg to 10 mg of MK-677 due to hyperglycemia (fasting glucose >140 mg/dl). Three of these subjects (3.6%) with persistently elevated glucose despite dose reduction were subsequently discontinued due to hyperglycemia. In the 2- and 4-week studies, increased values for serum glucose ranging from 126 mg/dl to 162 mg/dl were noted in 23% and 20% of the subjects, respectively, but no subject was discontinued due to hyperglycemia in these studies. The mean increase from baseline glucose in patients treated with MK-677 ranged from 5% to 10% in these studies. Elevations in hepatic serum transaminase activity were occasionally noted. In the 4-week study, 7% of subjects (n = 2) receiving MK-677 had reversible (1.5–2.5 greater than the upper limit of normal) increases in serum transaminase values. Transaminase elevations were not noted in the 2- or 9-week studies in any subject receiving MK-677. Finally, in the 9-week study, a mean increase from baseline serum prolactin of 27% was observed, but post-treatment values remained within the physiologic range.
https://asbmr.onlinelibrary.wiley.com/doi/10.1359/jbmr.1999.14.7.1182
From the laboratory perspective, hyperglycemia was the most common adverse effect after MK-677 treatment. In the 9-week study, five patients (6%) had their dose reduced from 25 mg to 10 mg of MK-677 due to hyperglycemia (fasting glucose >140 mg/dl). Three of these subjects (3.6%) with persistently elevated glucose despite dose reduction were subsequently discontinued due to hyperglycemia. In the 2- and 4-week studies, increased values for serum glucose ranging from 126 mg/dl to 162 mg/dl were noted in 23% and 20% of the subjects, respectively, but no subject was discontinued due to hyperglycemia in these studies. The mean increase from baseline glucose in patients treated with MK-677 ranged from 5% to 10% in these studies. Elevations in hepatic serum transaminase activity were occasionally noted. In the 4-week study, 7% of subjects (n = 2) receiving MK-677 had reversible (1.5–2.5 greater than the upper limit of normal) increases in serum transaminase values. Transaminase elevations were not noted in the 2- or 9-week studies in any subject receiving MK-677. Finally, in the 9-week study, a mean increase from baseline serum prolactin of 27% was observed, but post-treatment values remained within the physiologic range.
https://asbmr.onlinelibrary.wiley.com/doi/10.1359/jbmr.1999.14.7.1182
